(HOLX) Hologic - Ratings and Ratios

Hologic, Inc. (NASDAQ:HOLX) is a global leader in womens health and diagnostics, specializing in the development, manufacturing, and distribution of cutting-edge medical products. The company operates through four distinct segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Its comprehensive portfolio includes molecular diagnostic assays, medical imaging systems, and surgical solutions designed to improve patient outcomes through early detection and treatment.

In the Diagnostics segment, Hologic offers a range of Aptima molecular assays for detecting infectious microorganisms, including viral load testing for Hepatitis B and C, HIV, and cytomegalovirus, as well as assays for bacterial vaginosis, candida vaginitis, and SARS-CoV-2. The company also provides the ThinPrep System for cytology applications and the Rapid Fetal Fibronectin Test to assess pre-term birth risk. These solutions are complemented by the Panther Fusion system, which integrates PCR-based testing for streamlined workflows.

The Breast Health segment focuses on innovative solutions for breast cancer care, including 3D digital mammography systems, image analytics software, and minimally invasive biopsy guidance systems. Additionally, the company offers products for breast-conserving surgery, such as biopsy site markers and specimen radiology solutions, to enhance surgical accuracy and patient care.

In the GYN Surgical segment, Hologic provides advanced tools for gynecologic procedures, including the MyoSure Hysteroscopic Tissue Removal System for fibroid and polyp removal, the NovaSure Endometrial Ablation System for treating abnormal uterine bleeding, and the Acessa ProVu system for minimally invasive fibroid treatment. The Fluent Fluid Management System and CoolSeal bipolar vessel sealing devices further enhance procedural efficiency and safety.

The Skeletal Health segment includes the Horizon DXA dual-energy X-ray system for bone density measurements and the Fluoroscan Insight FD mini C-arm for orthopedic surgical procedures. These systems provide precise imaging capabilities, enabling accurate diagnoses and treatments in osteoporosis and orthopedic care.

Hologic distributes its products through a combination of direct sales, independent distributors, and sales representatives, ensuring broad market reach. Founded in 1985 and headquartered in Marlborough, Massachusetts, the company has established itself as a pioneer in womens health and diagnostics, with a strong commitment to innovation and patient care.

Ticker Symbol: HOLX Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Health Care Equipment

3-Month Forecast: - Price Action: Based on the SMA crossover and ATR, HOLX is expected to trade within a range of $56 to $62 over the next three months, with potential resistance at $61.71 (SMA 50) and support at $58.19 (last price). - Volatility: The ATR of 1.79 suggests moderate price fluctuations, with average daily moves of 3%. - Momentum: The downward trend in SMA 20 and SMA 50 indicates bearish momentum, but the forward P/E of 13.42 and RoE of 15.59 may attract value investors. - Volume: Average daily volume of 2.8 million shares is expected to remain stable, with potential spikes during earnings or macroeconomic events. - Valuation: The P/S ratio of 3.25 and P/B of 2.68 suggest moderate valuation, with upside potential driven by earnings growth.